



Online Supplementary Material

Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US. *JHEOR*. 2025;12(2):27-31. [doi:10.36469/jheor.2025.143106](https://doi.org/10.36469/jheor.2025.143106)

Table S1: Dosing Schedules Used in the CEPHEUS and IMROZ Clinical Trials

This supplementary material has been provided by the authors to give readers additional information about their work.



Table S1. Dosing Schedules Used in the CEPHEUS and IMROZ Clinical Trials^{6,7}

IMROZ	Induction phase: Cycle 1-4 (6-week cycles)																						
	Day	1	2	4	5	8	9	11	12	14	15	21	22	23	25	26	29	30	32	33	42		
	Isatuximab (10 mg/kg)	X				X ^a					X		X ^a				X						
	Bortezomib (1.3 mg/m ²)	X		X		X		X					X		X		X		X				
	Lenalidomide (25 mg) ^b	Days 1-14													Days 22-35								
	Dexamethasone (20 mg)	X ^c	X	X ^c	X	X ^c	X	X ^c	X		X ^c			X ^c	X	X ^c	X	X ^c	X	X ^c	X		
	Continuous phase: Cycle 5 onward (4-week cycles) until the occurrence of disease progression, an unacceptable adverse event, or other discontinuation criteria																						
	Isatuximab (10 mg/kg), cycle 5-17	X										X											
	Isatuximab (10 mg/kg), cycle 18+	X																					
	Lenalidomide (25 mg) ^b	Days 1-21																					
Dexamethasone (20 mg)	X					X					X		X										
CEPHEUS	Cycle 1-8 (3-week cycles)																						
	Day	1	2	4	5	8	9	11	12	14	15	21	22	23	25	26	29	30	32	33	42		
	Daratumumab (1800 mg), cycles 1-2	X				X					X												
	Daratumumab (1800 mg), cycles 3-8	X																					
	Bortezomib (1.3 mg/m ²)	X		X		X		X															
	Lenalidomide (25 mg)	Days 1-14																					
	Dexamethasone (20 mg)	X ^d	X	X ^d	X	X ^d	X	X ^d	X														
	Continuous phase: Cycle 8 onward (4-week cycles) until progression or unacceptable toxicity																						
	Daratumumab (1800 mg)	Once every 4 weeks																					
	Lenalidomide (25 mg)	Days 1-21																					
Dexamethasone (40 mg)	X ^e					X ^e						X ^e		X ^e									
*Cycle 1 only. *10 mg per day if the estimated glomerular filtration rate was 30 to <60 ml per minute per 1.73 m ² . *Patients ≥75 years receive dexamethasone only on these days. *Patients >75 years or body mass index <18.5 km/m ² receive dexamethasone only on these days. *20 mg for patients >75 years or body mass index <18.5 km/m ² .																							